This inventor holds 1 USPTO granted patent. Top assignee: Zeneca Limited. Active years: 1997.
Company Filing History:
Years Active: 1997
Title: Andrew Firman Wright: Innovator in Tumor-Associated Antigens
Introduction
Andrew Firman Wright is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target tumor-associated antigens. His work has implications for cancer research and treatment.
Latest Patents
Wright holds a patent for "Antibodies recognizing tumor associated antigen CA 55.1." This patent describes antibodies that recognize a tumor-related antigen designated CA55.1, including hybridoma 55.1, which is deposited as ECACC deposit no. 93081901. The complementarity determining regions of these antibodies have specific sequences that enhance their effectiveness in targeting cancer cells.
Career Highlights
Wright is associated with Zeneca Limited, a company known for its innovative approaches in pharmaceuticals and biotechnology. His work at Zeneca has allowed him to focus on developing solutions that address critical health challenges, particularly in oncology.
Collaborations
Throughout his career, Wright has collaborated with esteemed colleagues, including Christopher Boot and Susan Margaret Hall. These partnerships have fostered a collaborative environment that promotes innovation and the advancement of scientific knowledge.
Conclusion
Andrew Firman Wright's contributions to the field of biotechnology, particularly in the development of tumor-associated antibodies, highlight his role as an influential inventor. His work continues to pave the way for advancements in cancer treatment and research.